US12572Q1058 - Common Stock

Taking everything into account, **CME** scores **5** out of 10 in our fundamental rating. **CME** was compared to 207 industry peers in the **Capital Markets** industry. **CME** has only an average score on both its financial health and profitability. While showing a medium growth rate, **CME** is valued expensive at the moment.

In the past 5 years **CME** always reported a positive cash flow from operatings.

Measured over the past 3 years, the **Average Return On Invested Capital** for **CME** is in line with the industry average of **9.53%**.

The last **Return On Invested Capital** (**17.68%**) for **CME** is above the 3 year average (**7.80%**), which is a sign of increasing profitability.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 2.4% | ||

ROE | 10.7% | ||

ROIC | 17.68% |

ROA(3y)1.51%

ROA(5y)1.98%

ROE(3y)9.15%

ROE(5y)8.62%

ROIC(3y)7.8%

ROIC(5y)7.16%

In the last couple of years the **Profit Margin** of **CME** has declined.

In the last couple of years the **Operating Margin** of **CME** has grown nicely.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 80.31% | ||

PM (TTM) | 28.15% | ||

GM | N/A |

OM growth 3Y7.23%

OM growth 5Y2.65%

PM growth 3Y-1.43%

PM growth 5Y-19.88%

GM growth 3YN/A

GM growth 5YN/A

The number of shares outstanding for **CME** has been increased compared to 5 years ago.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.12 | ||

Debt/FCF | 1.06 | ||

Altman-Z | 0.89 |

ROIC/WACCN/A

WACCN/A

A Current Ratio of **1.03** indicates that **CME** should not have too much problems paying its short term obligations.

Looking at the **Current ratio**, with a value of **1.03**, **CME** is in line with its industry, outperforming **42.65%** of the companies in the same industry.

A Quick Ratio of **1.03** indicates that **CME** should not have too much problems paying its short term obligations.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 1.03 | ||

Quick Ratio | 1.03 |

The **Earnings Per Share** has grown by an nice **15.16%** over the past year.

The **Earnings Per Share** has been growing by **10.89%** on average over the past years. This is quite good.

The **Revenue** has been growing by **14.64%** on average over the past years. This is quite good.

EPS 1Y (TTM)15.16%

EPS 3Y5.48%

EPS 5Y10.89%

EPS growth Q2Q13.64%

Revenue 1Y (TTM)76.16%

Revenue growth 3Y9.44%

Revenue growth 5Y14.64%

Revenue growth Q2Q36.38%

The **Earnings Per Share** is expected to grow by **5.75%** on average over the next years.

The **Revenue** is expected to grow by **4.54%** on average over the next years.

EPS Next Y14.91%

EPS Next 2Y8.74%

EPS Next 3Y7.1%

EPS Next 5Y5.75%

Revenue Next Year8.73%

Revenue Next 2Y6.32%

Revenue Next 3Y5.56%

Revenue Next 5Y4.54%

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

With a **Price/Earnings** ratio of **23.93**, **CME** is valued on the expensive side.

Compared to the rest of the industry, the **Price/Earnings** ratio of **CME** indicates a slightly more expensive valuation: **CME** is more expensive than 72.55% of the companies listed in the same industry.

When comparing the **Price/Earnings** ratio of **CME** to the average of the S&P500 Index (**24.81**), we can say **CME** is valued inline with the index average.

The average S&P500 **Price/Forward Earnings** ratio is at **19.91**. **CME** is around the same levels.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 23.93 | ||

Fwd PE | 22.55 |

Based on the **Enterprise Value to EBITDA** ratio, **CME** is valued cheaply inside the industry as 83.33% of the companies are valued more expensively.

Compared to the rest of the industry, the **Price/Free Cash Flow** ratio of **CME** is on the same level as its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 23.13 | ||

EV/EBITDA | 8.89 |

PEG (NY)1.6

PEG (5Y)2.2

EPS Next 2Y8.74%

EPS Next 3Y7.1%

With a **Yearly Dividend Yield** of **2.02%**, **CME** has a reasonable but not impressive dividend return.

Compared to an average industry **Dividend Yield** of **8.08**, **CME** is paying slightly less dividend.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 2.02% |

The dividend of **CME** has a limited annual growth rate of **4.49%**.

Dividend Growth(5Y)4.49%

Div Incr Years4

Div Non Decr Years4

DP106.23%

EPS Next 2Y8.74%

EPS Next 3Y7.1%

**CME GROUP INC**

NASDAQ:CME (12/6/2023, 11:49:51 AM)

**212.74**

**-5.6 (-2.56%) **

Chartmill FA Rating

GICS SectorFinancials

GICS IndustryGroupFinancial Services

GICS IndustryCapital Markets

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap76.58B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 2.02% |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 23.93 | ||

Fwd PE | 22.55 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)1.6

PEG (5Y)2.2

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 2.4% | ||

ROE | 10.7% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 80.31% | ||

PM (TTM) | 28.15% | ||

GM | N/A | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.09

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.12 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 1.03 | ||

Quick Ratio | 1.03 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)15.16%

EPS 3Y5.48%

EPS 5Y

EPS growth Q2Q

EPS Next Y14.91%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)76.16%

Revenue growth 3Y9.44%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y